Engflag

Lanzapin

Quick links to important sections

Lanzapin

There is no image.

Method of action: Analgesic, Analgesic (Opioid), Anesthetic, Pain Reliever, Sedative

Treatment option: Pain, Pain Management, Shingles, Pain, Breakthrough, Cancer, Heart Attack, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanzapin

Quick Facts

Property Description
Active Ingredient Fentanyl (often as Fentanyl citrate)
Pharmacological Class Opioid Analgesic / Pure Opioid Agonist
Common Use Providing analgesia for severe pain
Origin Synthetic (Phenylpiperidine derivative)
Form Injection solution, Transdermal patch, Transmucosal forms

Lanzapin: Definition and Pharmacological Class

Lanzapin is a medication containing the active ingredient fentanyl, which is defined as a highly potent synthetic opioid. Unlike natural opioids, fentanyl is chemically manufactured as a phenylpiperidine derivative, placing it within the pharmacological class of narcotic analgesics and pure opioid agonists. This classification indicates that the medicine provides relief by activating opioid receptors in the body. The fundamental role of fentanyl is recognized for its ability to manage pain in situations where less potent alternatives are insufficient.

Primary Forms and General Therapeutic Purpose

The drug is a single-ingredient product available in diverse dosage forms, including the injection solution, the controlled-release transdermal patch (an adhesive matrix), and rapid systems like the oral transmucosal lozenge. These preparations facilitate various routes of administration, such as intravenous, transdermal, and sublingual, optimizing its delivery for patient needs. The primary general therapeutic purpose of Lanzapin is to provide analgesia, offering relief for severe pain. This use highlights its specific function in blocking intense pain signals, often employed for patients requiring continuous opioid therapy.

How Lanzapin Provides Pain Relief: A High-Level Concept

Lanzapin provides pain relief by acting on the central nervous system (CNS), including the brain and spinal cord, where it engages specific opioid receptors. The active substance is highly lipophilic, allowing it to rapidly cross the blood-brain barrier to initiate its analgesic effects quickly. By mimicking the action of the body's natural pain-dampening chemicals, endorphins, the medication effectively interrupts the transmission of pain signals to the brain, which is the underlying mechanism for its pain control.

Regulatory References

  1. Fentanyl MeSH Descriptor Data (NIH/NLM)
  2. Fentanyl Drug Facts (NIH/NIDA)

What side effects are possible with Lanzapin?

Possible Side Effects and Safety Information

The safety characteristics of Lanzapin (Fentanyl) are defined by government regulatory documents, outlining both common adverse reactions and serious, life-threatening risks. These reactions are formally grouped by frequency and the body system affected, consistent with standard regulatory reporting.

Adverse Reaction Classification

Adverse reactions are classified according to incidence rates derived from clinical data, often using regulatory frequency bands:

  • Very Common (ge 1 in 10 patients): Nausea, vomiting, constipation, dizziness, somnolence, and headache are frequently documented.
  • Common (ge 1 in 100 to < 1 in 10 patients): Effects such as shortness of breath (dyspnoea), pruritus, sweating, anxiety, confusion, and insomnia are noted.

Reported effects are formally categorized by System-Organ-Classes (SOC), including Nervous System Disorders, Gastrointestinal Disorders, and Psychiatric Disorders.

Serious Safety Concerns and Restrictions

The official labeling mandates prominent warnings regarding several serious safety concerns. The most critical risk is life-threatening respiratory depression, which is typically greatest when treatment is initiated or following a dose increase. Other serious documented risks include the potential for Opioid Dependence, Tolerance, and Addiction, Severe Hypotension, and Neonatal Opioid Withdrawal Syndrome if used regularly during pregnancy.

Regulatory documents also detail specific safety patterns and constraints:

  • Time-Related Patterns: Respiratory depression with transdermal forms may be delayed, occurring later due to the drug's depot effect. Certain non-serious effects are often more frequently observed at the start of treatment.
  • Population Notes: Specific caution is advised for older adults and patients with renal or hepatic impairment due to the potential for altered drug clearance and increased sensitivity to adverse effects.
  • Safety Limitations: Due to its potential for Abuse and Misuse, and the risk of fatal respiratory depression, certain formulations are strictly contraindicated in patients who are not already opioid-tolerant.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Lanzapin

Overdose Scope

Domain Official Regulatory Statements
Documented overdose presentations: Symptoms include life-threatening respiratory depression, often manifesting as shallow or slow breathing, progressing to profound sedation and coma. Other signs include pinpoint pupils (miosis), cyanosis of the lips and skin, and a limp body.
Physiological systems affected (as stated in label): Primarily the Central Nervous System (CNS), resulting in severe neurological and respiratory depression, and the Cardiovascular System, potentially leading to severe cardiovascular depression.
Dose-related or exposure-related factors (if applicable): Excessive exposure is the primary factor. The risk of Serotonin Syndrome is noted in the context of concomitant serotonergic drug administration.
Population-specific overdose notes (if applicable): Elderly, cachectic, or debilitated patients are noted to have an increased risk of life-threatening respiratory depression. Infants exposed through breast milk must be monitored for signs of excess sedation.
Emergency-response statements (as written in official documents): Administration of the specific opioid antagonist Naloxone is required. Intervention involves securing a patent airway and utilizing assisted or controlled ventilation.
When immediate medical help is required (label-derived phrasing only): Immediate medical attention must be sought upon suspicion or observation of overdose signs. Emergency services must be contacted immediately.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents): Overdose is classified as a life-threatening medical emergency.
Regulatory basis (EMA / FDA / etc.): Information is based on official prescribing information and monographs from government-authorized regulatory bodies.
Overdose-context constraints (as defined in official documents): Management is based on symptomatic and supportive treatment, including the close monitoring of vital signs, particularly respiratory status.

Resulting Overdose Structure

Official overdose statements:

  • Life-threatening respiratory depression is the major hazard, requiring immediate intervention due to the risk of respiratory arrest and death.
  • The specific opioid antagonist Naloxone must be administered to reverse the effects of overdose.
  • The occurrence of profound sedation or cyanosis necessitates immediate medical attention.

Connection to the overall overdose profile (3 sentences): The official regulatory documents define the Lanzapin overdose profile by its acute danger, focusing on the immediate threat posed by CNS and respiratory depression. This documentation explicitly links the observed signs, such as slowed breathing and unconsciousness, directly to the mandatory action of seeking immediate medical attention and administering the specific antidote. The entire regulatory structure dictates that all such manifestations must be managed as a life-threatening medical emergency requiring specialized supportive care.

Therapeutic Uses of Lanzapin

What Lanzapin Treats: Main Uses and Benefits

Lanzapin provides high-level analgesic support, which is commonly utilized in clinical settings for severe symptomatic discomfort. The medication is used to address symptoms related to severe pain and is relevant in contexts where additional support for symptom management is needed. Its primary therapeutic goal contributes to easing the overall symptom load and supports improved comfort during periods of high-intensity pain.

The medicine is commonly used across conditions presenting with significant symptomatic burden, including the management of persistent symptoms, addressing acute pain following major operations, and specifically targeting breakthrough pain—sudden, severe increases in symptoms despite stable baseline treatment. It is also applied across domains where additional symptomatic support is needed, serving as an analgesic adjunct during surgical procedures.

“It supports patients during episodes of heightened discomfort and contributes to easing distress and assists with functional stability when symptoms are more noticeable.”

This supportive relief helps patients cope more steadily with symptom fluctuations and assists with functional stability during phases when symptoms become more noticeable.

Quick Fact: Relief for Severe Discomfort
Main Symptom Axis Pain symptoms related to heightened physiological activity.
Primary Indication Conditions characterized by periods of severe, persistent symptoms.
Key Clinical Scenario Applied during phases of acute postoperative distress or episodic flare-ups.
Patient Benefit Contributes to improved comfort and supports comfort during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lanzapin (Olanzapine) — Official Regulatory Information

Contraindications: Populations Who Must NOT Use This Medicine

The following groups are strictly prohibited from using this medicine based on official regulatory documentation:

  • Elderly Patients with Dementia-Related Psychosis: Use is contraindicated and associated with an increased risk of death, a risk so significant that a Boxed Warning is issued, and the drug is not approved for this condition.
  • Known Hypersensitivity: Patients with a documented, known allergy or hypersensitivity to the medication.
  • Opioid Use: The combination product containing olanzapine and samidorphan is contraindicated in patients using opioids or undergoing acute opioid withdrawal.

Age-Related Eligibility

Age Group Eligibility Status (Monotherapy)
Under 13 Years Safety and effectiveness are not established. The drug is not approved for this age group.
13-17 Years Approved for the treatment of schizophrenia and bipolar I disorder.

Conditions Requiring Special Consideration

A lower starting dose should be considered for patients with established hepatic (liver) impairment or renal (kidney) impairment, as clinical experience is limited. Use also requires caution in individuals with a history of seizures or conditions that may lower the seizure threshold.

What should I know about interactions with other medicines?

Lanzapin Interactions with other medicines and products

Official regulatory information outlines several categories of interacting substances and specific restrictions concerning Lanzapin (fentanyl).

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited due to the risk of severe potentiation and Serotonin Syndrome. A mandatory separation period of 14 days is required when switching between an MAOI and Lanzapin. Other combinations classified as contraindicated include Alvimopan (in opioid-tolerant patients) and agents like Thalidomide, which increase the risk of profound respiratory depression.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Category Regulatory Outcome Statement
Pharmacokinetic (CYP3A4) Strong and Moderate CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) May result in increased fentanyl plasma concentrations and exposure, raising the risk of potentially fatal respiratory depression.
Pharmacokinetic (CYP3A4) CYP3A4 Inducers (e.g., Enzalutamide, Rifampin) May cause decreased fentanyl plasma concentrations, risking a loss of analgesic efficacy. Discontinuation of an inducer can lead to a sudden increase in fentanyl levels.
Pharmacodynamic (Additive) Central Nervous System (CNS) Depressants (e.g., Benzodiazepines, sedatives, alcohol) Results in an additive effect that increases the risk of profound sedation, respiratory depression, coma, and death.
Pharmacodynamic (Serotonergic) Serotonergic Drugs (e.g., SSRIs, SNRIs) Increases the risk of developing a potentially life-threatening Serotonin Syndrome.

Non-Medicinal Product and External Restrictions

The regulatory profile includes specific warnings against non-medicinal substances and conditions. Alcohol is noted to greatly increase CNS depressant effects, and the official label advises against its use. For the transdermal patch, the application site must not be exposed to external heat (e.g., heating pads, hot baths), as this is officially documented to increase the rate of fentanyl absorption and raise plasma concentrations.

Mechanism of Action

How Lanzapin Works: Pharmacodynamic Mechanism

Lanzapin's mechanism centers on its ability to act as an antagonist (blocker) at multiple central nervous system receptors, primarily the Dopamine D2 and Serotonin 5-HT2A receptors. This dual antagonism modulates the activity within the mesolimbic and mesocortical dopaminergic pathways, influencing neurochemical dynamics and modulating heightened neurochemical activity .

This polypharmacology extends to other binding sites, including antagonism of Histamine H1 receptors and alpha1-adrenergic receptors. Antagonism of H1 receptors alters central histamine activity, resulting in a state of lower wakefulness. alpha1 blockade interferes with vascular tone mediated by these receptors. Additionally, the mechanism is associated with changes in specific metabolic and homeostatic pathways, impacting glucose and lipid metabolism over time, leading to changes in metabolic homeostasis.

Dosage and Administration Information

Lanzapin is administered through multiple routes, including intravenous (IV) and intramuscular (IM) injection solutions, the transdermal system (patch), and transmucosal forms such as lozenges or buccal tablets. The choice of route is directly tied to the intended delivery pattern. For acute or surgical administration, IV or IM use is common, with doses ranging from fixed microgram amounts (e.g., 50 to 100 mcg) to weight-based calculations.

In contrast, the transdermal patch system is utilized for continuous, long-term delivery, with the dose expressed as a nominal release rate in micrograms per hour (mu g/hr). This patch is replaced at a fixed interval of every 72 hours to maintain a steady concentration. Dosage adjustments (titration) for chronic therapy are scheduled conservatively, not occurring more frequently than every three days. The rapid-acting transmucosal forms are reserved for as-needed (PRN) use for breakthrough episodes and are limited to specific dosing intervals, such as a minimum of 4 hours between treatments.

Specific procedural steps apply for proper administration. For transdermal use, the patch is applied to intact, non-irritated skin, and external heat sources are avoided at the application site. Transmucosal units are sucked slowly over a defined period (e.g., 15 minutes) and not chewed or swallowed. Furthermore, initial doses for older adults or debilitated patients are appropriately reduced across all formulations.

Recent Clinical Evidence

Research evidence / Overview of studies for Lanzapin

Evidence for Use in Acute Postoperative Pain

Research was studied for acute pain immediately following major operations and primarily involved short-term Randomized Controlled Trials (RCTs). These studies were designed to evaluate how quickly outcomes related to physical discomfort change after administration, often comparing the medicine to other options studied in acute pain management. Researchers focused on measuring changes in pain intensity scores, recorded over short observation intervals, and studying the consumption patterns when the medicine was delivered using patient-controlled devices.

Studies reported measurements of change in pain intensity scores, typically over the course of minutes, during the initial post-surgical recovery phase. The findings describe how symptoms evolved in the observed populations during the specific measurement intervals after administration. This evidence contributes to understanding symptom patterns during this phase.

Evidence for Use in Breakthrough Cancer Pain

Research examining Lanzapin was studied for Breakthrough Cancer Pain (BTCP)—sudden, severe pain flare-ups that occur despite stable baseline treatment—and utilized highly specific study designs, including randomized, double-blind, cross-over trials. These studies focused on rapid-acting formulations and were designed to measure changes in outcomes related to physical discomfort over rapid time intervals. The populations included were strictly opioid-tolerant adult cancer patients who were already receiving consistent opioid therapy for their underlying pain.

Studies reported measurements of change in pain intensity scores shortly after treating an episode of breakthrough pain. Data showed patterns related to the timeframes over which patient-reported outcomes describing perceived discomfort were monitored in the rapid-onset formulations. The findings contribute to understanding symptom patterns during these severe, acute episodes.

Research Gaps and Areas of Uncertainty

The evidence landscape highlights several areas where research is ongoing and certainty remains low. A significant limitation is the absence of robust, long-term RCT evidence (duration ge 1 year) concerning the sustained outcomes of Lanzapin therapy, particularly for chronic persistent pain. Data for certain groups, such as children, pregnant individuals, or those with specific comorbid conditions, remain insufficient. While findings describe group patterns observed in the studies, research provides context but not individual predictions of whether a person will respond similarly.

Key Studies & References Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis

Frequently Asked Questions (FAQ)

Common questions about Lanzapin (FAQ)

Q: What is Lanzapin used for?

Lanzapin is an antipsychotic medication. It is indicated for the treatment of certain mental health conditions, including schizophrenia and episodes associated with bipolar I disorder. The specific uses are determined by regulatory approval.

Q: How does Lanzapin work?

The exact way Lanzapin exerts its effects is not fully understood. It is believed to act on several chemical messengers in the brain, such as dopamine and serotonin receptors. Studies suggest this action may help manage symptoms associated with its indicated conditions.

Q: What is the effectiveness of Lanzapin supported by?

Effectiveness is supported by data from controlled clinical trials. These studies have observed that Lanzapin, compared to placebo, was associated with an improvement in scores on standard psychiatric rating scales for the indicated conditions. However, individual responses may vary.

Q: What are the common side effects of Lanzapin?

The most frequently reported adverse effects in clinical trials include drowsiness, dizziness, weight gain, and dry mouth. A healthcare professional can provide a complete list and discuss individual risk factors.

Q: Is Lanzapin safe to stop taking suddenly?

Sudden discontinuation of Lanzapin may be associated with the return of symptoms or other unwanted effects. Any change to a treatment plan should always be made under the guidance of a qualified healthcare provider.

How should Lanzapin be stored and disposed of?

Official Storage and Disposal Requirements

Storage & Disposal Scope Official Regulatory Requirement
Labeled Storage Temperature Store most formulations at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F) [3.3].
Handling/Protection Keep in the original, unopened package and protect from light and freezing [3.3], [4]. Oral forms must be protected from moisture [1].
Child-Protection Storage Mandatory: The medicine must be kept out of the sight and reach of children and secured in a lockbox or secure location at all times [1.7], [3.7].
Disposal Instructions Used or unused transdermal patches must be folded (adhesive sides together) and immediately flushed down the toilet to prevent accidental exposure (FDA mandate) [2.1], [2.7].

Official instructions define strict storage constraints and handling rules for Lanzapin [3.3]. The medicine must be stored at controlled room temperature and kept in its original packaging [1]. Due to its high potency, regulators strictly mandate that the product be kept securely locked away from children [3.7]. The disposal of patches is explicitly managed by regulatory bodies, requiring immediate flushing to minimize the risk of accidental poisoning [2.7].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagColombia

Equivalent of Lanzapin found in:

A-Z Index: